Tools
Tools
Lamond, Nathan W D, Skedgel, Christopher 
ORCID: https://orcid.org/0000-0003-4989-8846, Rayson, Daniel and Younis, Tallal
(2015)
Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.
Current Oncology, 22 (4).
e246-e253.
ISSN 1198-0052
Preview |
PDF (Lamond, 2015 Curr Onc)
- Published Version
Download (628kB) | Preview |
Abstract
BACKGROUND: Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-stage breast cancer and low levels of estrogen (lle) because of induced or natural menopause. Characterizing the cost-utility (cu) of this therapy could help to determine its role in clinical practice. METHODS: Using the perspective of the Canadian health care system, we examined the cu of adjuvant endocrine therapy with or without za in women with early-stage endocrine-sensitive breast cancer and lle. A Markov model was used to compute the cumulative costs in Canadian dollars and the quality-adjusted life-years (qalys) gained from each adjuvant strategy, discounted at a rate of 5% annually. The model incorporated the dfs and fracture benefits of adjuvant za. Probabilistic and one-way sensitivity analyses were conducted to examine key model parameters. RESULTS: Compared with a no-za strategy, adjuvant za in the induced and natural menopause groups was associated with, respectively, $7,825 and $7,789 in incremental costs and 0.46 and 0.34 in qaly gains for cu ratios of $17,007 and $23,093 per qaly gained. In one-way sensitivity analyses, the results were most sensitive to changes in the za dfs benefit. Probabilistic sensitivity analysis suggested a 100% probability of adjuvant za being a cost-effective strategy at a threshold of $100,000 per qaly gained. CONCLUSIONS: Based on available data, adjuvant za appears to be a cost-effective strategy in women with endocrine-sensitive breast cancer and lle, having cu ratios well below accepted thresholds.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | adjuvant therapy,zoledronic acid,breast cancer,bone health,cost–utility,economic analyses,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) |
| Related URLs: | |
| Depositing User: | Pure Connector |
| Date Deposited: | 19 Nov 2015 08:15 |
| Last Modified: | 22 Oct 2022 00:21 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/55409 |
| DOI: | 10.3747/co.22.2383 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |